SI-Bone (NASDAQ: SIBN) is one of 121 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare SI-Bone to related businesses based on the strength of its earnings, valuation, dividends, institutional ownership, analyst recommendations, risk and profitability.
This table compares SI-Bone and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares SI-Bone and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|SI-Bone||$55.38 million||-$17.45 million||-21.31|
|SI-Bone Competitors||$1.48 billion||$146.48 million||39.08|
SI-Bone’s peers have higher revenue and earnings than SI-Bone. SI-Bone is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
39.5% of SI-Bone shares are held by institutional investors. Comparatively, 50.8% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 15.9% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a summary of current recommendations for SI-Bone and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SI-Bone presently has a consensus price target of $24.75, suggesting a potential upside of 63.58%. As a group, “Surgical & medical instruments” companies have a potential upside of 29.01%. Given SI-Bone’s stronger consensus rating and higher probable upside, equities research analysts clearly believe SI-Bone is more favorable than its peers.
SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.